Provided by Tiger Fintech (Singapore) Pte. Ltd.

BIOCYTOGEN-B

21.500
-0.250-1.15%
Volume:112.00K
Turnover:2.42M
Market Cap:8.59B
PE:233.47
High:22.050
Open:21.600
Low:21.350
Close:21.750
Loading ...

Biocytogen Enters Into Antibody Licensing Agreement With Beone Medicines to Accelerate Innovative Drug Development

THOMSON REUTERS
·
10 Jul

HK Movers | Biotech Stocks Surge With JW Therap up 20%, RemeGen up 13%

Tiger Newspress
·
24 Jun

HBM Holdings Ltd. Successfully Defends Patent on Human Heavy Chain-Only Antibodies in China

Reuters
·
16 Jun

Biocytogen Pharmaceuticals Announces Share Repurchase Plan

Reuters
·
13 Jun

Biocytogen Pharmaceuticals Secures Japan Patent for RenMab Platform, Expanding Global Patent Portfolio

Reuters
·
05 Jun

Biocytogen and Nanjing Chia Tai Tianqing Announce Ind Approval in China for Co-Developed Anti-Igf-1R Antibody Ntb003 (Bcg009)

THOMSON REUTERS
·
05 Jun

BRIEF-Biocytogen And Nanjing Chia Tai Tianqing Announce Ind Approval In China For Co-Developed Anti-Igf-1R Antibody Ntb003 (Bcg009)

Reuters
·
04 Jun

Biocytogen and Nanjing Chia Tai Tianqing Announce Ind Approval in China for Co-Developed Anti-Igf-1R Antibody Ntb003 (Bcg009)

THOMSON REUTERS
·
04 Jun

BUZZ-HK-listed Biocytogen reaches 2-month high on DeepSeek integration

Reuters
·
28 Feb

Biocytogen Pharmaceuticals to Turn to 2024 Profit

MT Newswires Live
·
21 Feb

Biocytogen Pharmaceuticals (Beijing) Anticipates Turn to Profit in 2024

MT Newswires Live
·
27 Jan

BRIEF-Biocytogen Pharmaceuticals Beijing Sees FY Revenue To Be Between RMB969.3 Mln And RMB989.3 Mln

Reuters
·
27 Jan

Biocytogen Pharmaceuticals Beijing - FY Revenue Expected to Be About RMB969.3 Mln to RMB989.3 Mln

THOMSON REUTERS
·
27 Jan

Biocytogen Pharmaceuticals Beijing Co Ltd - Expected Result Due to Recognition of Antibody Discovery Business by Overseas Customers, Others

THOMSON REUTERS
·
27 Jan